Navigation Links
Boston Scientific Announces Schedule for EuroPcr 2007

Company to release broad range of clinical data on leading drug-eluting stent portfolio

NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the annual Paris Course on Revascularization (EuroPCR), which will runs from May 22 to 25 in Barcelona, Spain.

"We will be announcing new data from several of our clinical trials and registries, adding to the knowledge base for treating coronary artery disease," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "Pooled data from our ARRIVE registries will shed light on key predictors for stent thrombosis in real-world DES use. Additional data will provide insight into the performance of our market-leading TAXUS(R) paclitaxel-eluting stent systems as well as our new everolimus-based PROMUS(TM) (XIENCE(TM) V) stent system, reinforcing Boston Scientific's role as the only company offering two distinct drug-eluting stent platforms."

    Schedule of Events (all times are local Barcelona)


    Tuesday, May 22


    * The Great Debate on DES.  The Company will host a symposium entitled

      "The Great Debate on Coronary Drug-Eluting Stents," chaired by Jean

      Marco, M.D., and Steven Nissen, M.D., from 1:30 - 3:15 p.m. in Room 1 of

      The Centre de Convencions Internacional de Barcelona.  Experts will

      debate and answer questions from interventional cardiologists related to

      coronary drug-eluting stent usage in daily practice.


    * TAXUS VI four-year data.  At 5:01 p.m., Professor Eberhard Grube, M.D.,

      will present four-year results from the TAXUS VI trial in a late-

      breaking session.  This randomized, double-blind trial is designed to

      assess the safety and efficacy of a moderate-release (non-

      commercialized) formulation paclitaxel-eluting stent versus a bare metal

      stent control group.  Data will be presented on examined s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boston Scientific Announces Schedule for EuroPcr
(Date:11/25/2009)...rlandsandJOHANNESBURG,November25/PRNewswire/--,iTh...ryannouncedtoday,thattheyhavesignedacollaborativea..., Pyxis,sworldclasscomputationalchemistryandlea...icedivisiontoprovidemedicinaland,syntheticchemistr...ionalclientnetwork.iThembaPharmaceuticalsandPyxisD...
(Date:11/24/2009)....24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgianma...ccident,wasactuallyfullyconsciousandawakeduringtha...TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillustrat...anunlockcommunication. ,, WHEN:GoodMorningAmeri...ynavoxtech.com ,, WHO:RomHoubenswasanengine...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--AnadysPharmaceuticals,Inc...he21stAnnualPiperJaffrayHealthcareConferenceonTues...nferenceisbeingheldatTheNewYorkPalaceHotel.SteveWo...dys,willprovideanoverviewofAnadysanditsclinicaldev...tepresentationwillbesimultaneouslywebcastandcanbea...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2CombinatoRx and Neuromed Sign Merger Agreement 50637 1CombinatoRx and Neuromed Sign Merger Agreement 50637 2CombinatoRx and Neuromed Sign Merger Agreement 50637 3CombinatoRx and Neuromed Sign Merger Agreement 50637 4CombinatoRx and Neuromed Sign Merger Agreement 50637 5CombinatoRx and Neuromed Sign Merger Agreement 50637 6CombinatoRx and Neuromed Sign Merger Agreement 50637 7CombinatoRx and Neuromed Sign Merger Agreement 50637 8CombinatoRx and Neuromed Sign Merger Agreement 50637 9Triple S Management Corporation Schedules Second Quarter Earnings Release and Webcast 50633 1Triple S Management Corporation Schedules Second Quarter Earnings Release and Webcast 50633 2Study Casts Doubt on Low IQs Role in Early Death 50630 1Study Casts Doubt on Low IQs Role in Early Death 50630 2
...technologies, inc., a privately held company focus...peutics (MAbs) for cancer, today announced it,is c...lerated dose cohort,expansion segment of its Phase...ointestinal tract that express the RAAG12 antigen.... widely found on the,surface of tumor cells of man...
...LC,announced today that their drug KX2-391 (KX01) ...tled "A combined rising single-dose (RSD) and,risi...afety, tolerability,and pharmacokinetics of KX2-39...refractory to conventional therapies". The drug be... treatments called protein kinase inhibitors., Do...
Other Medicine Technology:Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 2Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 3First Patient Dosed with KX2-391 in Phase 1 Clinical Trial 2
(Date:11/25/2009)...tigue, forgetfulness could lead mothers to overloo..., Nov. 25 (HealthDay News) -- A mother,s depressio...have found. , Their six-month study of 262 blac...hose mothers had more depressive symptoms had more...rs with fewer depressive symptoms had less frequen...
(Date:11/25/2009)... more positive note, CDC sees few signs of trouble...Nov. 25 (HealthDay News) -- The ongoing H1N1 swine...gerous pneumonias among younger patients, a U.S. h... an increase in serious pneumococcal infections ar...the National Center for Immunization and Respirato...
(Date:11/25/2009)...,, ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/-...reventHealthCareFraudActof2009,"S.2128,whichisdesi...letopreventfraudinMedicare.ThebillwasintroducedbyS...ainsseveralprovisionstheAmericanAssociationforHome...htheAssociationproposedtoCongressinFebruary.Thosep...
(Date:11/25/2009)...CAMBRIDGE, Mass. -- A cancer vaccine carried into ...ed implant is the first to successfully eliminate ...the journal Science Translational Medicine . , ...munologists at Harvard University, uses plastic di...mplanted under the skin to reprogram the mammalian...
(Date:11/25/2009)...The serious behavior problems that can occur in ch...educed with a treatment plan that includes medicat...r parents, according to Yale University researcher...mber 2009 issue of the Journal of the American Ac...dy was conducted by the National Institute of Ment...
Breaking Medicine News(10 mins):Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2
... anti-TNF agents (etanercept) and chemotherapy dru...he treatment of Rheumatoid Arthritis.// Furthermor...erably slowed down in over three quarters of patie...reatment measures. ENBREL is the only solubl...
...s received US Food Drug Administration (US FDA) ap...mg and 50 mg in the US.// Promethazine is an a...nd reactions, to cause sedation, to assist in cont...timated at $116 million. The group had recently ...
...rial disorder that can lead to a multitude of comp...ted on animal models suggests the possibility of u...sorder. More specifically, //it has been found to ...s with diabetes. This provided a simulation of the...
...rly 50 nursery school children has revealed that m...t on to their children as well, //resulting in ele...s hormones were considerably higher amongst the gr...e other hand, children of women who enjoyed their ...
...up has been shortlisted by Britain's National Heal...s in the UK where it could provide diagnostic serv...d it to outsource some of its operations to cut th...a-sound and so on. 'Our bidding team is in London...
...ildenafil) can improve exercise capacity and funct...hypertension, a serious disease involving high pre... new study suggests.// According to a report ...ive Viagra, at one of three doses, or inactive pla...
Other Medicine News:Health News:Combination Therapy With ENBREL And Methotrexate Found Effective In RA Treatment 2Health News:Children’s Stress Levels Directly Related To Maternal Job Satisfaction 2Health News:Apollo Hospitals Short-listed to Provide Diagnostics in the UK 2
Surgical Loupes
...lity full-coverage body imaging. New Freewave data...tecture. New powerful Quasar Dual gradients design...200. New RF-Smart developed for SAR management to ...ronment. Sense is an essential element for imaging...
...er negative lens delivering magnification of 2.0x,... ease of use. Movement whilst maintaining focal cl...field. The ultra lightweight aluminum bar and indi...y for the mounted loupes and optimal focal alignme...
...presents a breakthrough for patients experiencing ...he system gathers bone during decompression, bone ...g of bone into the implant's chamber produces a lo...m the iliac crest. The BAK/C implant is constructe...
Medicine Products: